Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|---|---|---|---|
|
·¹¹ÌÄÉÀ̵åÁÖ100mg - »õâ
|
Schering-Plough |
E04060351 | Infliximab | Àü¹®ÀǾàǰ | »èÁ¦ | ºÐ¾÷¿¹¿ÜÀǾàǰ |
|
·¹¹ÌÄÉÀ̵åÁÖ»ç100mg - »õâ
|
½¦¸µÇª¶ó¿ìÄÚ¸®¾Æ |
E04060461 | Infliximab | Àü¹®ÀǾàǰ | ±Þ¿© |
| Remicade |
infliximab: an anti-TNF compound (trade name Remicade) consisting of an antibody directed against TNF; it is given intravenously at one-month to three-month intervals; used in treatment of regional enteritis and rheumatoid arthritis
Ãâó: wordnet.princeton.edu/perl/webwn
|
|---|---|
| Remicade |
Infliximab (Remicade®) is a powerful drug used to treat auto-immune disorders like Crohn's disease and rheumatoid arthritis. Infliximab is known as a "chimeric monoclonal antibody" (the term "chimeric" refers to the use of both mouse and human components of the drug i.e. mouse binding VK and VH domains and human constant Fc domains). ...
Ãâó: en.wikipedia.org/wiki/Remicade
|
| Remicade |
Trademark for a drug containing infliximab, used in the treatment of Crohn
Ãâó: www.gastrolab.net/dicter.htm
|
| Remicade | an anti-TNF compound (trade name Remicade) consisting of an antibody directed against TNF |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|